Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version
December 9, 2020

Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version

By Matsuoka
Background: The rise within the variety of most cancers circumstances and the evolution of most cancers care administration have turn out to be a big downside for the French well being care system, thereby making affected person empowerment as a protracted sought-after purpose in continual pathologies. The implementation of an activation measure through the Affected person Activation Measure-13 merchandise (PAM-13) in the midst of most cancers care can probably spotlight the affected person’s wants, with nursing care adapting accordingly.
Goal: The goals of this PARACT (PARAmedical Interventions on Affected person ACTivation) multicentric research have been as follows: (1) consider the implementation of PAM-13 in oncology nursing practices in 5 complete most cancers facilities, (2) determine the obstacles and facilitators to the implementation of PAM-13, and (3) produce suggestions for the dissemination of such interventions in different complete most cancers facilities.
Strategies: This research will comply with the “Attain, Effectiveness, Adoption, Implementation, and Upkeep” framework and can consist of three phases. First, a strong preimplementation evaluation will probably be performed utilizing the Theoretical Domains Framework (TDF) linked to the “Functionality, Alternative, Motivation, and Conduct” mannequin to determine the obstacles and facilitators to implementing new nursing practices in every context. Then, utilizing the Conduct Change Wheel, we are going to personalize a technique for implementing the PAM-13, relying on the specificities of every context, to encourage acceptability by the nursing employees concerned within the mission. This evaluation will probably be carried out through a qualitative research by way of semistructured interviews.
Second, the affected person will probably be included within the research for 12 months, throughout which the affected person care pathway will probably be studied, significantly to gather all related contacts of oncology nurses and different well being professionals concerned within the pathway. The axes of nursing care may even be collected. The first purpose is to implement PAM-13. Secondary elements to be measured are the affected person’s nervousness stage, high quality of life, and well being literacy stage. The oncology nurses will probably be liable for finishing the questionnaires when the affected person is on the hospital for his/her intravenous chemotherapy/immunotherapy remedy. The questionnaires will probably be accomplished thrice in a 12 months: (1) on the time of the affected person’s enrollment, (2) at 6 months, and (3) at 12 months. Third, a postimplementation evaluation will probably be carried out by way of semistructured interviews utilizing the TDF to research the implementation issues at every website.
Outcomes: This research was supported by a grant from the French Ministry of Well being (PHRIP PARACT 2016-0405) and the Lucien Neuwirth Institute of Cancerology of Saint-Etienne, France. Knowledge assortment for this research is ongoing.
Conclusions: This research would enhance the carried out focused nursing interventions in most cancers facilities so {that a} affected person is obtainable a customized most cancers care pathway. Moreover, measuring the extent of activation and the implementation of measures meant to extend such activation may represent a big benefit in decreasing social well being inequalities.

Navigating uncharted waters: Creating a standardized method for evaluating and implementing biosimilar merchandise at a complete most cancers middle

Goal: The processes for formulary implementation and digital well being file (EHR) integration of biosimilar merchandise at a complete most cancers middle are described. Implications for analysis protocols are additionally mentioned.
Abstract: The present literature focuses on sensible concerns for formulary addition of biosimilar merchandise, however there’s a lack of steering on how you can implement the change, significantly throughout the EHR. Earlier than constructing the ordering instruments for biosimilars, the scientific and informatics groups ought to decide the function of biosimilars on the establishment, determine drug-specific product traits that have an effect on treatment construct, and characterize implications of future formulary adjustments or drug shortages. Leveraging an orderable file supplies the power to incorporate logic that maps to a number of merchandise and in addition permits for future implementation of adjustments throughout the treatment file fairly than requiring “swaps” on the remedy protocol stage. The institutional overview board ought to coordinate adjustments in affected analysis protocols and consent kinds and work with principal investigators to amend protocols when obligatory. Pharmacy leaders ought to develop processes to supervise stock in the course of the transition interval and decrease the chance of errors.
Conclusion: The event of a standardized method for evaluating and implementing biosimilar merchandise improves effectivity and collaboration among the many numerous group members liable for the merchandise’ integration into present workflows, together with implications for scientific analysis. Implementing biosimilars for brokers used to deal with most cancers will pose new challenges and require extra concerns. Partial implementation of biosimilars continues to pose a number of challenges within the provision of affected person care.
Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version

Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version

Matrix stiffness epigenetically regulates the oncogenic activation of the Sure-associated protein in gastric most cancers

In lots of cancers, tumour development is related to elevated tissue stiffness. But, the mechanisms associating tissue stiffness with tumorigenesis and malignant transformation are unclear. Right here we present that in gastric most cancers cells, the stiffness of the extracellular matrix reversibly regulates the DNA methylation of the promoter area of the mechanosensitive Sure-associated protein (YAP). Reciprocal interactions between YAP and the DNA methylation inhibitors GRHL2, TET2 and KMT2A may cause hypomethylation of the YAP promoter and stiffness-induced oncogenic activation of YAP.

Breast cancer

BR724 each
EUR 270
Description: Breast cancer, adjacent and adjacent normal tissue array, 66 cases/72 cores

Breast cancer

BR725 each
EUR 270
Description: Breast cancer, adjacent and adjacent normal tissue array, 68 cases/72 cores

Human Cancer Antigen 15-3 (CA 15-3) ELISA Kit

PRB-5069 96 assays
EUR 686.4

Human Cancer Antigen 15-3 (CA 15-3) ELISA Kit

PRB-5069-5 5 x 96 assays
EUR 2739.6

Gastrointestinal Cancer Antigen (CA 19-9), antigen grade

CA1991-N-10 10 KU
EUR 634.8

Cancer Antigen 15-3 MUC 1 Antigen (Human Milk)

VAng-Cr3871-10kU 10 kU
EUR 505.2
Description: Cancer Antigen 15-3 MUC 1 Antigen, Host/Source: Human Milk. The purity is detected by salt extraction and delipidization following high speed centrifugation. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2.

Paraffin Tissue Section - Human Breast Tumor: Lobular carcinoma

T2235086-3 5 slides
EUR 308.4
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Breast Cancer-Associated Antigen BRCAA1 (BRCAA1) Antibody

20-abx148333
  • EUR 510.00
  • EUR 410.40
  • 100 ug
  • 50 ug

Breast tumor tissue array (15 of 25)

BR20821 each
EUR 474
Description: Breast tumor tissue array (15 of 25), including TNM, clinical stage, pathology grade and IHC markers (ER, PR, Her-2) results,104 cases/208 cores

BSA (Standard Grade)

30-AB70 1 kg
EUR 1078.8
Description: Standard Grade Bovine Serum Albumin (99% pure)

Cancer Antigen 15-3 MUC 1 Antigen (Human Ascites Fluid)

VAng-Cr3872-10kU 10 kU
EUR 1363.2
Description: Cancer Antigen 15-3 MUC 1 Antigen, Host/Source: Human Ascites Fluid.

Cancer Antigen CA 15-3 Protein (Human Fluids)

VAng-Wyb8628-inquire inquire Ask for price
Description: CA 15-3 (Breast Cancer Antigen), Cancer antigen from Human Fluids, 12.240 kU/mL.

Cancer Antigen CA 15-3 Protein (Human Milk)

VAng-Wyb8631-inquire inquire Ask for price
Description: CA 15-3 (Breast Cancer Antigen), Antigen Grade, Cancer antigen from Human Milk, 33.0 kIU/mL.

Paraffin Tissue Section - Human Brain Tumor: Astrocytoma Grade III

T2235035-3 5 slides
EUR 308.4
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Breast cancer with cancer adjacent breast tissue array

BC081116e each
EUR 306
Description: Breast cancer with cancer adjacent breast tissue array, including invasive carcinoma of no special type, breast carcinoma with apocrine differentiation and AT tissue,pat hology grade, IHC (ER/PR/Her-2/Ki67) info, TNM/Stage (AJCC 7th edition), 107 cases/110 cores (core size 1.5mm), replacing BC081116d

Cancer Antigen 15-3 (CA15-3) (human) ELISA Kit

K4804-100 100 assays
EUR 1000.8
Description: Sensitive, Colorimetric Assay

Breast cancer TMA

BR602 each
EUR 270
Description: Breast cancer TMA, 3 samples have matched cancer adjacent tissue samples, including pathology grade, TNM and clinical stage (reference AJCC 8th version), 57 cases/60 cores (Core Size 1.5mm), recent tear collections

Organic Wine Standard 3

WINE-3 1ML
EUR 258.78

Human Cancer PrimaCell4: Breast Tumor Cells Growth Medium

9-46027 5 x 100 ml Ask for price

Breast cancer with matched cancer adjacent breast tissue array

BR804b each
EUR 306
Description: Breast cancer with matched cancer adjacent breast tissue array, including pathology grade, TNM, clinical stage and IHC markers (ER, PR, Her-2 and Ki67), 40 cases/80 cores, replacing BR804a

Breast cancer with breast tissue array

BC08118a each
EUR 258
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 100 cases/100 cores (core size 1.0mm), replacing BC08118

Breast cancer with breast tissue array

BR2085d each
EUR 546
Description: Breast cancer with breast tissue array, including pathology grad, TNM and clinical stage, 188 cases/208 cores, replacing BR2085c

Breast cancer with breast tissue array

BR246d each
EUR 66
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage (reference AJCC 7th version), 12 cases/24 cores, replacing BR246c

Breast cancer with breast tissue array

BR482 each
EUR 198
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 24 cases/48 cores

Breast cancer with breast tissue array

BR720 each
EUR 270
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical satge (reference AJCC 7th version), 72 cases/72 cores

Breast cancer with breast tissue array

T087d each
EUR 66
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T087c

Breast cancer with breast tissue array

T088d each
EUR 66
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T088c

Human Cancer Tissue Preparation Buffer 4: Breast Tumor Cells

9-80027 1 x 100 ml Ask for price

Breast cancer tissue array

BR042b each
EUR 78
Description: Breast cancer tissue array, including TNM and pathology grade, 4 cases/4 cores, replacing BR042a

Breast cancer tissue array

BR1006a each
EUR 306
Description: Breast cancer tissue array, including pathology grade, TNM and clinical stage, 50 cases/100 cores (core size 1.0mm), replacing BR1006

Breast cancer tissue array

BR1141a each
EUR 354
Description: Breast cancer tissue array, including pathology grade, TNM and clinical stage, IHC marker (ER, PR, HER2 and Ki-67), 114 cases/114 cores, replacing BR1141

Breast cancer tissue array

BR1401 each
EUR 414
Description: Breast cancer tissue array, including TNM and pathology grade, IHC markers ER/PR/Her-2 results, 140 cases/140 cores (core size 1.0mm)

Breast cancer tissue array

BR1503f each
EUR 306
Description: Breast cancer tissue array, including TNM and pathology grade, with IHC results of Her-2\ER\PR\Ki67, 75 cases/ 150 cores, replacing BR1503e

Breast cancer tissue array

BR1505e each
EUR 306
Description: Breast cancer tissue array, including pathology grade, TNM, clinical stage, and IHC(HER2/ER/PR/Ki67), 75 cases/150 cores, replacing BR1505d

Breast cancer tissue array

BR2161 each
EUR 546
Description: Breast cancer tissue array, including TNM and pathology grade, 216 cases/216 cores

Breast cancer tissue array

BR247a each
EUR 234
Description: Breast cancer tissue array, with normal tissue, including TNM and pathology grade, IHC marker (HER2), 24 cases/48 cores replacing BR247

Breast cancer tissue array

BR488 each
EUR 306
Description: Breast cancer tissue array, including pathology grade, TNM, clinical stage (AJCC 7th edition), and IHC marker(ER,PR,Her-2), 48 cases/48 cores

Breast cancer tissue array

BR501 each
EUR 270
Description: Breast cancer tissue array, including TNM and pathology grade, 50 cases/ 50 cores (core size 1.5mm)

Breast cancer tissue array

BR8015a each
EUR 306
Description: Breast cancer tissue array, with adjacent normal tissue and normal tissue, including TNM and pathology grade, 80 cases/80 cores, replacing BC08014

Breast cancer tissue array

BR964 each
EUR 222
Description: Breast cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases/96 cores

Breast cancer tissue array

T089c each
EUR 48
Description: Breast cancer tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores(1.5mm), replacing T089b

Breast cancer and normal tissue array with stage and grade info

BR8012 each
EUR 306
Description: Breast cancer and normal tissue array with stage and grade info, 40 cases/80 cores, replaced by BR8014

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit

DLR-CA15-3-Hu-48T 48T
EUR 574.8
Description: A sandwich quantitative ELISA assay kit for detection of Human Carbohydrate Antigen 15-3 (CA15-3) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit

DLR-CA15-3-Hu-96T 96T
EUR 745.2
Description: A sandwich quantitative ELISA assay kit for detection of Human Carbohydrate Antigen 15-3 (CA15-3) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit

RDR-CA15-3-Hu-48Tests 48 Tests
EUR 600

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit

RDR-CA15-3-Hu-96Tests 96 Tests
EUR 830.4

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit

RD-CA15-3-Hu-48Tests 48 Tests
EUR 573.6

Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit

RD-CA15-3-Hu-96Tests 96 Tests
EUR 794.4

99445-15 DCT 15 X 85MM

99445-15 250/pk
EUR 116.4
Description: Disposable Culture Tubes; DCT's, CGW

Multiple breast cancer with breast tissue array

BR087e each
EUR 48
Description: Multiple breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing BR087d

Breast cancer with matched breast tissue array

BR251e each
EUR 60
Description: Breast cancer with matched breast tissue array, including pathology grade, IHC info (ER,PR,Her-2,Ki67),TNM\Stage, 6 cases/24 cores (core size 1.5mm), replacing BR251d

Fluorescent Exosome Standard (Urine )

ESF-15 100 µg
EUR 2067.6
Description: Fluorescent exosomes are labeled with green dye, which offer a stable fluorescent labeling.

Breast cancer tissue array with cancer adjacent breast tissue as control

BR208a each
EUR 474
Description: Breast cancer tissue array with cancer adjacent breast tissue as control, including TNM, clinical stage and pathology grade, 69 cases/ 207 cores.

CA 15-3, Human Breast Adenocarcinoma

P1435-1 each
EUR 130.8

CA 15-3, Human Breast Adenocarcinoma

P1435-5 each
EUR 288

Inactivated CMV Grade 3 Antigen

VAng-Lsx0038-1mg 1 mg
EUR 2503.2
Description: CMV Grade 3, natural protein.

Inactivated MuV Grade 3 Antigen

VAng-Lsx0411-inquire inquire Ask for price
Description: MuV grade 3, native protein.

Inactivated Rotavirus Grade 3 Antigen

VAng-Lsx0469-inquire inquire Ask for price
Description: Rotavirus Grade 3, native virus.

Inactivated RuV Grade 3 Antigen

VAng-Lsx0476-1mL 1 mL
EUR 474
Description: RuV Grade 3, natural protein.

Cancer Antigen 242 Antigen

VAng-Cr3876-10kU 10 kU
EUR 505.2
Description: Cancer Antigen 242 Antigen, Host/Source: Metastatic Liver. The purity is detected by gel filtration.

Cancer Antigen 50 Antigen

VAng-Cr3877-50kU 50 kU
EUR 6642
Description: Cancer Antigen 50 Antigen, Host/Source: Human Cell Culture. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2.

ICP-MS Calibration Standard 3

CL-CAL-3 125ML
EUR 121.98

Proteinase K, Recombinant, Standard Grade

9250-100 each
EUR 124.8

Proteinase K, Recombinant, Standard Grade

9250-10G each
EUR 4627.2

Proteinase K, Recombinant, Standard Grade

9250-1G each
EUR 548.4

Proteinase K, Recombinant, Standard Grade

9250-500 each
EUR 314.4

Proteinase K, Recombinant, Standard Grade

9251-100 each
EUR 1266

Proteinase K, Recombinant, Standard Grade

9251-25 each
EUR 352.8

Proteinase K, Recombinant, Standard Grade

9251-5 each
EUR 144

Breast cancer (including one case of male breast cancer) with adjacent normal breast tissue array

BC081120g each
EUR 306
Description: Breast cancer (including one case of male breast cancer) with adjacent normal breast tissue array, including pathology grade, TNM and clinical stage (AJCC 7th edition) with IHC results ER/PR/Her2/Ki67,110 cases/110 cores (core size 1.0 mm), replacing BC081120f

Breast cancer with adjacent normal breast tissue array

BR1921c each
EUR 546
Description: Breast cancer with adjacent normal breast tissue array, including pathology grade, TNM, clinical stage and IHC marker (ER, PR and Her-2), 189 cases/192 cores, replacing BR1921b

Breast disease spectrum (breast cancer progression) tissue array

BR2082c each
EUR 546
Description: Breast disease spectrum (breast cancer progression) tissue array, including pathology grade, TNM and clinical stage, IHC marker (ER, PR, HER2 and Ki-67), 186 cases/192 cores, replacing BR2082b

Breast cancer with adjacent normal breast tissue array

BR803c each
EUR 258
Description: Breast cancer with adjacent normal breast tissue array, including pathology grade, TNM and clinical stage, 80 cases/80 cores, replacing BR803b

Breast cancer with adjacent normal breast tissue array

BR901a each
EUR 270
Description: Breast cancer with adjacent normal breast tissue array, including pathology grade, TNM and clinical stage, 45 cases/90 cores, replacing BR901

Breast normal tissue with breast cancer tissue array

BRN801c each
EUR 270
Description: Breast normal tissue with breast cancer tissue array, including pathology grade, TNM and clinical stage, 80 cases/80 cores, replacing BRN801b

Polystyrene Particle Size Standard

PPS-3 mL
EUR 152.4
Description: Please reffer to the technical data sheet for more detail information for this item. Our dedicated team would be happy to assist you via live chat, email or phone.

Breast Cancer Metastasis Suppressor 1

PR27265 2 ug
EUR 229.2

Breast cancer test tissue array

T086e each
EUR 66
Description: Breast cancer test tissue array, including TNM, clinical stage and pathology grade, 12 cases/24 cores, replacing T086d

Breast Tumor Kinase antibody

70R-31875 100 ug
EUR 392.4
Description: Rabbit polyclonal Breast Tumor Kinase antibody

Breast Tumor Kinase antibody

70R-33385 100 ug
EUR 392.4
Description: Rabbit polyclonal Breast Tumor Kinase antibody

Breast Tissue Lysate (Tumor)

1713-01 0.1 mg
EUR 336.3
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1713-02 0.1 mg
EUR 336.3
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1714-01 0.1 mg
EUR 336.3
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1714-02 0.1 mg
EUR 336.3
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1714-03 0.1 mg
EUR 336.3
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1714-04 0.1 mg
EUR 336.3
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1714-05 0.1 mg
EUR 336.3
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1714-06 0.1 mg
EUR 336.3
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Breast Tissue Lysate (Tumor)

1714-07 0.1 mg
EUR 336.3
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol.

Human Breast Tumor lysate

HTL-1323 1 mg
EUR 927.6

Breast Membrane Tumor Lysate

XBL-10499 0.1 mg
EUR 752.1
Description: Human breast tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human breast tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated breast tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated breast tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal.

ICP-MS Instrument Check Standard 3

CL-ICS-3 125ML
EUR 175.56

Cancer Antigen 72-4 Antigen

VAng-Cr3878-10kU 10 kU
EUR 505.2
Description: Cancer Antigen 72-4 Antigen, Host/Source: Metastatic Liver. The purity is ~65% by SDS-PAGE. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2.

Advanced stage breast cancer and normal breast tissue array

BR1191 each
EUR 306
Description: Advanced stage breast cancer and normal breast tissue array, including pathology grade, TNM and clinical stage (AJCC 8.0), ER\PR\HER-2\Ki-67 marker, 119 cases/119 cores, (1.5mm)

Breast cancer tissue array with adjacent normal breast tissue

BR8011a each
EUR 306
Description: Breast cancer tissue array with adjacent normal breast tissue, including TNM, clinical stage, pathology grade and DCIS, 80 cases/80 cores, replacing BR8011

Breast cancer with matched or unmatched breast tissue array

BR802c each
EUR 270
Description: Breast cancer with matched or unmatched breast tissue array, including pathology grade, TNM and clinical stage, 53 cases/80 cores, replacing BR802b

Human CA15-3 Antigen Grade Protein

abx060972-250kU 250 kU
EUR 2380.8

Inactivated PIV-3 Grade 2 Antigen

VAng-Wyb3637-1mL 1 mL
EUR 1363.2
Description: Parainfluenza virus type 3 (strain C243) Grade 2, natural antigen

Inactivated HSV-1 Grade 3 Antigen

VAng-Lsx0293-1mg 1 mg
EUR 1786.8
Description: HSV Type 1 Grade III, native antigen.

Inactivated HSV-2 Grade 3 Antigen

VAng-Lsx0302-1mg 1 mg
EUR 1786.8
Description: HSV Type 2 Grade III, native antigen.

Microplate cell grade 96well ps standard

781965 PK50
EUR 347.47

Prostate Specific Antigen Std Grade Antigen

VAng-Cr3891-1mg 1 mg
EUR 604.8
Description: Prostate Specific Antigen Std Grade Antigen, Host/Source: Human Seminal Fluid. The purity is detected by salt precipitation.

CEA Antigen Grade Protein

abx060976-05mg 0.5 mg
EUR 1161.6

CEA Antigen Grade Protein

abx060977-1mg 1 mg
EUR 2030.4

Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody

20-abx171475
  • EUR 1028.40
  • EUR 526.80
  • 1 mg
  • 200 ug

Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody

20-abx133658
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody

20-abx129227
  • EUR 510.00
  • EUR 159.60
  • EUR 1446.00
  • EUR 693.60
  • EUR 393.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody

20-abx013807
  • EUR 376.80
  • EUR 117.60
  • EUR 477.60
  • EUR 594.00
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg

Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody

abx025588-400ul 400 ul
EUR 627.6

Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody

abx025588-80l 80 µl
EUR 343.2

Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody

20-abx324781
  • EUR 376.80
  • EUR 292.80
  • 100 ug
  • 50 ug

Recombinant Breast Cancer Anti-Estrogen Resistance 3 (BCAR3)

4-RPG768Hu01
  • EUR 601.69
  • EUR 284.40
  • EUR 1926.34
  • EUR 722.11
  • EUR 1324.22
  • EUR 477.60
  • EUR 4635.84
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Human Breast Cancer Anti-Estrogen Resistance 3 expressed in: E.coli

9998 SCREW CAP 415/15

9998-15 288/pk
EUR 237.6
Description: General Apparatus; Stoppers

Pesticide Mix 3 Containing 15 Compounds in Acetonitrile

SPXPR-3 1ML
EUR 214.32

Breast Cancer and 8 types of tumor (middle advanced stage)tissue array

BR20838a each
EUR 474
Description: Breast Cancer and 8 types of tumor (middle advanced stage)tissue array, including pathology grade, TNM/stage with IHC Her-2 results, 118 cases/208 cores (core size 1.5mm), replacing BR20838

Breast Cancer Metastasis Suppressor 1 Protein

20-abx263402
  • EUR 1930.80
  • EUR 393.60
  • EUR 276.00
  • 100 ug
  • 10 ug
  • 2 µg

Autobioluminescent Human Breast Cancer Cells (MCF7)

ASE-5903 1 ml
EUR 2490
Description: 6 month

Autobioluminescent Human Breast Cancer Cells (T47D)

ASE-5904 1 ml
EUR 2490
Description: 6 month

Human Breast Cancer Signaling Primer Library

HBRCA-I 1 set
EUR 657.6

Breast Cancer Anti-Estrogen Resistance 1

PR27245 2 ug
EUR 229.2

Anti-Breast Cancer Resistance Protein antibody

STJ16100903 1 mL
EUR 573.6

Anti-Breast Cancer Resistance Protein antibody

STJ16100916 1 mL
EUR 573.6

anti-Breast cancer suppressor candidate 1

YF-PA24096 50 ul
EUR 400.8
Description: Mouse polyclonal to Breast cancer suppressor candidate 1

anti-Breast cancer suppressor candidate 1

YF-PA12974 50 ul
EUR 435.6
Description: Mouse polyclonal to Breast cancer suppressor candidate 1

anti-Breast cancer suppressor candidate 1

YF-PA12975 50 ug
EUR 435.6
Description: Mouse polyclonal to Breast cancer suppressor candidate 1

Multiple types breast cancer tissue array

BR1003a each
EUR 306
Description: Multiple types breast cancer tissue array, including pathology grade, TNM and clinical stage, 47 cases/101 cores, replacing BR1003

Late stage breast cancer tissue array

BR1922 each
EUR 546
Description: Late stage breast cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases/192 cores

Poorly differentiated breast cancer tissue array

BR351a each
EUR 66
Description: Poorly differentiated breast cancer tissue array, including TNM, clinical stage and pathology grade, 35 cases/35 cores, replacing BR351

Breast cancer and normal tissue array

BR485 each
EUR 414
Description: Breast cancer and normal tissue array, including TNM and pathology grade, 2 serial sections, 48 cases/96 cores

High-density breast cancer tissue array

BR6161 each
EUR 954
Description: High-density breast cancer tissue array, with stage, grade and normal breast tissue, 322 cases/616 cores

Breast cancer and normal tissue array

BR8014 each
EUR 306
Description: Breast cancer and normal tissue array, including TNM, clinical stage and pathology grade, 40 cases/80 cores, replaced by BR8015

Breast tumor tissue array (3 of 5)

BR20834a each
EUR 546
Description: Breast tumor tissue array (3 of 5), including pathology grade, TNM and clinical stage, 208 cases/208 cores, replacing BR20834

Breast Tumor Tissue Array - 16 cases of breast cancer, each in duplicates, paired with adjacent normal tissues

Z7020007 5 slides
EUR 1657.2
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Breast cancer with matched metastatic carcinoma or breast tissue array

BRM961a each
EUR 384
Description: Breast cancer with matched metastatic carcinoma or breast tissue array, including pathology grade, TNM, clinical stage and IHC marker (ER, PR and Her-2), 49 cases/96 cores

Human Cancer Antigen CA15-3 Protein

abx060965-50kU 50 kU
EUR 3150

Breast Tumor Kinase Blocking Peptide

AF4768-BP 1mg
EUR 234

Breast Tumor Kinase antibody (Tyr447)

70R-33384 100 ug
EUR 392.4
Description: Rabbit polyclonal Breast Tumor Kinase antibody (Tyr447)

Human Tumor Tissue: Breast cDNA

HT05-090 10 rxn
EUR 498

Anti-Rabbit Whole Serum | GWS-15

GWS-15 1.0 mL
EUR 130
Description:

Anti-Rabbit Whole Serum | GWS-15 | Immunology Consultants Laboratory

Host: Goat

Format: Whole Serum

Product Type: Primary Antibody

Antibody Clonality: Polyclonal

Liquid Wicks, Size 15, 200 /pk

W-15 200 WICKS
EUR 22
Description: Liquid Wicks, Size 15, 200 /pk

Cancer Antigen 125 Antigen (Human Adenocarcinoma)

VAng-Cr3868-10kU 10 kU
EUR 505.2
Description: Cancer Antigen 125 Antigen, Host/Source: Human Adenocarcinoma. The purity is detected by salt extraction and chromatography.

Cancer Antigen 125 Antigen (Ascites Fluid)

VAng-Cr3870-10kU 10 kU
EUR 1132.8
Description: Cancer Antigen 125 Antigen, Host/Source: Ascites Fluid. The purity is ≥ 95% by SDS-PAGE.
Direct alteration of extracellular cues through in situ matrix softening reversed YAP exercise and the epigenetic program. Our findings recommend that epigenetic reprogramming of the mechanophysical properties of the extracellular microenvironment of stable tumours might symbolize a therapeutic technique for the inhibition of most cancers development.